For end-stage heart failure, a transplant replaces a failing heart with a donor organ. China's transplant centres concentrated in a small number of licensed, high-volume institutions perform large annual volumes with published 1-year survival consistently above 90% — among the best in the world — and at costs dramatically below Western self-pay rates.
What it treats & who qualifies
- End-stage heart failure refractory to maximal therapy (ischaemic, dilated, peripartum, congenital).
- Intractable arrhythmias or refractory angina unsuitable for revascularisation.
- Some congenital heart disease variants failing in adulthood (Fontan circulation, etc.).
- Psychosocial suitability and a committed follow-up structure at home — the Chinese team verifies both.
Why patients travel to China for this
- Major Chinese transplant centres publish 1-year survival above 90% and 5-year survival above 80% — matching or exceeding ISHLT international benchmarks — driven by concentrated volume at licensed centres.
- Waiting time for a matched organ at China's major centres is often shorter than at home because donor allocation within China's COTRS system is national and centrally coordinated.
- Self-pay all-in cost of roughly US$90,000–140,000 versus US$1.4M+ billed charges in the US.
Treatment options, compared
| Option | Best suited for | What it means in practice |
|---|
| Orthotopic heart transplantation | The definitive therapy | Published Chinese 1-year survival above 90% at major licensed centres. |
|---|
| VAD / artificial-heart bridge | Transplant candidates too sick to wait | Domestic Chinese VAD devices have made bridging affordable — an option that barely exists in most of Asia. |
|---|
| Optimised medical therapy + resynchronisation | Patients who can improve without transplant | Honest listing evaluation includes maximising what medicine can still do. |
|---|
The procedure, step by step
- Extensive work-up: blood type, HLA and antibody screening, cancer clearance, pulmonary vascular testing, psychosocial evaluation.
- Listing with the national organ allocation system (COTRS); patients usually stay near the centre while waiting.
- When a matched organ is allocated, the recipient is admitted; the donor heart is transported on ice or perfusion machine.
- The failed heart is excised and the donor heart is anastomosed (biatrial or bicaval technique); the heart is re-perfused and resumes beating.
- ICU recovery, immunosuppression induction, then staged rehabilitation and lifelong immunosuppression management.
Cost, hospital stay & recovery
| Typical China cost (reference only) | US$90,000–140,000 all-in (surgery + first-year base immunosuppression) |
|---|
| Typical in-hospital stay | ICU 5–10 days, ward 2–3 weeks; rehabilitation for 4–8 weeks before flying |
|---|
| Return-to-travel timeline | Lifelong immunosuppression and monitoring; endomyocardial biopsies per protocol |
|---|
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
Recovery, week by week
- Week 0–2: Work-up and listing; patients stay near the centre with family support arranged.
- Admission: When a matched organ is allocated, surgery happens within hours; ICU 5–10 days.
- Month 1: Ward rehabilitation; induction immunosuppression; biopsy surveillance begins.
- Month 2–3: Discharge and rehabilitation; fly home once stable; home team takes over with the full English file.
Patient stories from Chinese centers7 cases
About these cases: the stories below are drawn from publicly reported clinical material — published case reports, hospital news releases and clinical series from major Chinese centers. Names and identifying details have been changed or omitted. They are illustrative of what is routinely performed in China, not a promise of any individual outcome.
A 51-year-old man from the United States with end-stage cardiomyopathy
Years on a transplant waitlist with a LVAD conversation looming. He listed in China, was transplanted within weeks of evaluation, and returned home with complete operative records his US cardiologist now follows.
Source: Hospital-reported international transplant; anonymised.
A 46-year-old man from Italy with a failing graft
A previous bypass had exhausted its benefit. Transplantation in Beijing; the immunosuppression protocol was handed over to his Milan team at discharge, who continue it unchanged.
Source: Public clinical reports; anonymised.
A 44-year-old woman from the United Kingdom with peripartum cardiomyopathy
A heart that never recovered after her daughter's birth. Transplanted in China when her ejection fraction hit 12%; her daughter is now six, and her heart is borrowed and perfect.
Source: Hospital-reported transplant case; anonymised.
A 49-year-old man from Saudi Arabia with ischaemic cardiomyopathy
Multiple infarcts had hollowed his heart. Transplant evaluation in China moved from referral to surgery in under two months; he manages his follow-up locally with shared records.
Source: Published Chinese transplant registries; anonymised.
A 42-year-old man from the United Arab Emirates with giant-cell myocarditis
A rare, ferocious inflammation burned through his myocardium in weeks. Bridged with mechanical support, then transplanted in Shanghai during the same admission; he went home with a new heart and an old life back.
Source: Hospital-reported urgent transplant; anonymised.
A 39-year-old man from Vietnam with dilated cardiomyopathy
A young father with a terminal heart and no local programme. China's organ-donation system matched him in weeks; he was back at work in Ho Chi Minh City at month six.
Source: Public clinical reports; anonymised.
A 47-year-old woman from Malaysia with recurrent admissions
Defibrillator shocks and hospital admissions every few months. Transplant in Guangzhou, then structured follow-up shared between the Chinese team and her Kuala Lumpur cardiologist; her admissions are now annual check-ups, not emergencies.
Source: Hospital-reported transplant case; anonymised.
Frequently asked questions
Who licenses and oversees organ donation in China?
Donation and allocation run through China's national system (COTRS), with voluntary non-directed donation after death. Transplants for international patients are performed only at officially licensed centres; WellVoyage works exclusively within that licensed framework and documents the full chain.
Can my home centre manage my post-transplant care?
Yes, and that is the plan from day one: Chinese centres prepare a full English discharge pack — operative notes, immunosuppression levels, biopsy schedule — that your home transplant or heart-failure team continues against.
Medical disclaimer: WellVoyage is a medical-travel coordination service, not a medical provider. This guide is general information, not medical advice; treatment decisions rest with your treating physicians. Patient stories are drawn from publicly reported, anonymised material and do not promise any individual outcome. Cost figures are reference ranges; the binding price is your written quote. Hospitals and doctors named on this site are independent third parties, not our partners. In an emergency, contact your local emergency services immediately.